• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ABBV

    AbbVie Inc.

    Subscribe to $ABBV
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

    IPO Year: 2012

    Exchange: NYSE

    Website: abbvie.com

    Peers

    $AMGN
    $GILD
    $REGN
    $SNY
    $ABT
    $BMY
    $LLY
    $GSK
    $IQV
    $JNJ
    $NVS
    $PFE
    $TAK

    Recent Analyst Ratings for AbbVie Inc.

    DatePrice TargetRatingAnalyst
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    11/15/2024$205.00Outperform
    Wolfe Research
    11/4/2024Hold → Buy
    Argus
    10/17/2024$203.00Mkt Perform
    Bernstein
    6/5/2024$185.00Hold → Buy
    HSBC Securities
    5/17/2024$200.00Overweight
    Cantor Fitzgerald
    1/29/2024Mkt Perform → Outperform
    William Blair
    See more ratings

    AbbVie Inc. SEC Filings

    See more
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      4/25/25 7:48:22 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      4/3/25 4:13:07 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by AbbVie Inc.

      144 - AbbVie Inc. (0001551152) (Subject)

      3/31/25 5:30:00 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by AbbVie Inc.

      DEFA14A - AbbVie Inc. (0001551152) (Filer)

      3/24/25 4:28:59 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by AbbVie Inc.

      DEF 14A - AbbVie Inc. (0001551152) (Filer)

      3/24/25 4:28:10 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by AbbVie Inc.

      PRE 14A - AbbVie Inc. (0001551152) (Filer)

      3/10/25 5:05:17 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by AbbVie Inc.

      144 - AbbVie Inc. (0001551152) (Subject)

      3/3/25 5:57:29 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by AbbVie Inc.

      144 - AbbVie Inc. (0001551152) (Subject)

      2/28/25 5:37:47 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      2/26/25 5:04:39 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by AbbVie Inc.

      424B5 - AbbVie Inc. (0001551152) (Filer)

      2/20/25 5:00:33 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AbbVie Inc. Leadership Updates

    Live Leadership Updates

    See more
    • AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

      Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

      2/14/25 7:40:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs

      For immediate release iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs WAVRE, Belgium — 4 September 2024: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the strengthening of its leadership team with the appointment of Richard (Rick) Beckman, M.D., as Chief Medical Officer and member of the Board, and Kristine (Kris) Curtiss as Vice President of Clinical Affairs. Rick's duties as Chief Medical Officer (CMO) will cross clinical, regulatory, and medical affairs. Additionally, he will be a member of the Board. Rick brings deep insight and experience from

      9/4/24 7:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day

      Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024Members receive an exclusive gift card offer and a chance to win $10,000*IRVINE, Calif., July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21. After a successful first year, JUVÉDERM® Day is back with limited time offers, savings, and exclusive deals through Allē, the Allergan Aesthetics loyalty rewards program. "JUVÉDERM® Day 2023 logged the most treatments in a single day for the brand, and our goal is to surpass that this year. During this year's event, we are providing even more exclusi

      7/30/24 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer

      NORTH CHICAGO, Ill., July 10, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of executive vice president, research & development and chief scientific officer. In this position, Dr. Thakkar will lead the company's global R&D organization of more than 14,000 team members across all phases of discovery and development, including therapeutics and aesthetics. "Dr. Thakkar is a physician by training with a deep commitment to innovation and patient care," said Rob Michael, chief executive officer, AbbVie. "He has an excellent track record i

      7/10/24 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors

      Ms. Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent directorNORTH CHICAGO, Ill., June 20, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024. Ms. Austin succeeds Glenn F. Tilton, who has served as lead independent director since 2013. Mr. Tilton will continue to serve on the AbbVie Board as an independent director. "One of AbbVie's greatest strengths is an experienced, diverse and highly independent Board of Directors committed to the highest standards of corporate governance," said Richard A. Gonzalez, chairman and chief

      6/20/24 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SkinMedica® Celebrates 25 Years of Empowering Radiant Skin

      Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000IRVINE, Calif., June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To mark this milestone anniversary, Allē Members who purchase SkinMedica® products at a participating Allē Health Care Provider or SkinMedica.com from June 1 to June 25, 2024 can earn double points* and enter for a chance to win $5,000.** "For 25 years, SkinMedica® has been delivering scientifically based skincare to patients and helping them to unlock the potential to have beautiful skin," said Jasson Gilmore, Senior Vice Pr

      6/6/24 8:30:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50

      Join Allē Today to Start Sharing and Earning RewardsRefer a Friend by Allē Lets Consumers Earn up to $50 to Use Towards Allergan Aesthetics Products and TreatmentsIRVINE, Calif., June 4, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē, the Allergan Aesthetics Loyalty Rewards Program. Now, Allē Members can invite their friends and family to join and both parties can receive savings on Allergan Aesthetics products or treatments from brands like BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® Collection of Fillers, SKINVIVE by JUVÉDERM®, CoolSculpting®, SkinMedica®, and DiamondGlow®. "When you ar

      6/4/24 8:05:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

      Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunologyAbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by TentarixNORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's

      2/22/24 8:05:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AbbVie Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    AbbVie Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      10/18/24 4:38:13 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

      10/17/24 1:29:31 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

      6/21/24 4:38:17 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/20/2024. Application Category: BLA, Application Number: 761262, Application Classification:

      6/20/24 11:04:18 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-29) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761105, Application Classification:

      6/20/24 11:01:37 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for RINVOQ issued to ABBVIE INC

      Submission status for ABBVIE INC's drug RINVOQ (ORIG-1) with active ingredient UPADACITINIB has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218347, Application Classification: Type 3 - New Dosage Form

      4/29/24 11:33:31 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for RINVOQ LQ issued to ABBVIE INC

      Submission status for ABBVIE INC's drug RINVOQ LQ (ORIG-1) with active ingredient UPADACITINIB has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218347, Application Classification: Type 3 - New Dosage Form

      4/29/24 11:33:31 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-8) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 03/04/2024. Application Category: BLA, Application Number: 761262, Application Classification:

      3/5/24 4:43:23 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-27) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 03/04/2024. Application Category: BLA, Application Number: 761105, Application Classification:

      3/5/24 4:43:21 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-32) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 01/03/2024. Application Category: BLA, Application Number: 761105, Application Classification:

      1/4/24 8:55:06 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gonzalez Richard A gifted 2,450 shares, decreasing direct ownership by 0.63% to 386,479 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:15 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Alpern Robert J

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:16 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Quaggin Susan E

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:10 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Rapp Edward J

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:13 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 25,700 shares at a strike of $79.02 and sold $12,359,504 worth of shares (58,832 units at $210.08), decreasing direct ownership by 38% to 53,234 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:09 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Reents Scott T sold $3,746,527 worth of shares (17,644 units at $212.34), decreasing direct ownership by 60% to 11,577 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      3/18/25 5:00:22 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Purdue David Ryan claimed ownership of 5,032 shares (SEC Form 3)

      3 - AbbVie Inc. (0001551152) (Issuer)

      3/10/25 4:28:43 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, CONTROLLER Buckbee Kevin K covered exercise/tax liability with 3,699 shares, decreasing direct ownership by 32% to 7,797 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      3/4/25 5:00:33 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, R&D and CSO Thakkar Roopal covered exercise/tax liability with 4,678 shares, decreasing direct ownership by 10% to 42,276 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      3/4/25 5:00:28 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, GC AND SECRETARY Siatis Perry C sold $5,822,402 worth of shares (27,900 units at $208.69), exercised 18,008 shares at a strike of $159.88 and covered exercise/tax liability with 7,870 shares, decreasing direct ownership by 79% to 4,619 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      3/4/25 5:00:18 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AbbVie Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie to Present at the Bank of America Securities Healthcare Conference

      NORTH CHICAGO, Ill., May 6, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key ther

      5/6/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"

      BOTOX® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals.By 2030, BOTOX® Cosmetic Pledges to Empower 50,000 Entrepreneurs, Helping to Close the Confidence Gap.IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced BOTOX® Cosmetic's continued commitment to closing the Confidence Gap with the introduction of The Confidence Project: Empowering Women Entrepreneurs. The one & only BOTOX® Cosmetic invites business owners to apply for this year's program starting today through May 9, 2025, at 11:59pm PT.

      5/1/25 5:00:00 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

      –      RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults–      Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries2 –      This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology1 NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the European Commission recently granted marketing authoriza

      4/29/25 7:30:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Reports First-Quarter 2025 Financial Results

      Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis  First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues

      4/25/25 7:43:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

      –TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks. –If approved, TrenibotE will be the first neurotoxin of its kind available to patients.–Submission is supported by data from over 2,100 patients treated with TrenibotE throughout the clinical program.  NORTH CHICAGO, Ill., April 24, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines. "

      4/24/25 8:30:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New York Plastic Surgical Group and Deep Blue Med Spa Receive State and National Recognition by Allergan Aesthetics

      Garden City, NY, April 10, 2025 (GLOBE NEWSWIRE) -- New York Plastic Surgical Group and Deep Blue Med Spa have been named the #1 provider of Allergan products in New York State. In addition, they have been ranked in the top 25 nationally. This distinction places them in the top 1% of over 30,000 Allergan medical aesthetic practices throughout the country. As a pioneer in the field of aesthetic medicine, Allergan develops and manufactures a portfolio of leading brands and products including Botox Cosmetic, the Juvéderm family of fillers, Coolsculpting, Cooltone, DiamondGlow, and SkinMedica. To receive a top placement from such an authority within the industry is not only an accomplishment,

      4/10/25 9:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

      RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA)The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission †1This marks the eighth approved indication for RINVOQ in the EU2NORTH CHICAGO, Ill., April 8, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily

      4/8/25 2:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host First-Quarter 2025 Earnings Conference Call

      NORTH CHICAGO, Ill., March 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas in

      3/31/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

      Data for ABBV-969, a novel STEAP1/PSMA dual-targeted antibody-drug conjugate (ADC) in Phase 1 for advanced prostate cancer, will be presented in an oral presentation.Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors.Other presentations highlight key insights into treatment resistance and biomarker identification based on real-world-data analyses.NORTH CHICAGO, Ill., March 26, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Ann

      3/26/25 8:30:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

      Four expert-led educational events with Allergan Medical Institute (AMI), Science of AgingTM and Allergan Aesthetics (AA) Global Medical AffairsAMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de MaioEleven E-Poster data presentations and Meet the Expert sessions with Global experts live from the Allergan Aesthetics boothNORTH CHICAGO, Ill., March 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment

      3/24/25 4:02:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AbbVie Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/13/24 4:55:55 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      1/25/24 4:59:27 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/9/23 10:54:46 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/9/22 3:15:58 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/3/22 4:29:37 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/16/21 3:46:32 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/10/21 10:30:26 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AbbVie Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on AbbVie with a new price target

      Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $210.00

      4/22/25 7:59:33 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on AbbVie with a new price target

      BofA Securities resumed coverage of AbbVie with a rating of Neutral and set a new price target of $191.00

      12/10/24 8:12:28 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie downgraded by Daiwa Securities with a new price target

      Daiwa Securities downgraded AbbVie from Outperform to Neutral and set a new price target of $180.00

      12/5/24 7:33:20 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded AbbVie from Market Perform to Outperform and set a new price target of $206.00

      11/22/24 7:18:20 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on AbbVie with a new price target

      Wolfe Research initiated coverage of AbbVie with a rating of Outperform and set a new price target of $205.00

      11/15/24 7:28:42 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie upgraded by Argus

      Argus upgraded AbbVie from Hold to Buy

      11/4/24 8:22:15 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernstein initiated coverage on AbbVie with a new price target

      Bernstein initiated coverage of AbbVie with a rating of Mkt Perform and set a new price target of $203.00

      10/17/24 7:13:51 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie upgraded by HSBC Securities with a new price target

      HSBC Securities upgraded AbbVie from Hold to Buy and set a new price target of $185.00

      6/5/24 7:10:59 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on AbbVie with a new price target

      Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $200.00

      5/17/24 7:25:42 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie upgraded by William Blair

      William Blair upgraded AbbVie from Mkt Perform to Outperform

      1/29/24 7:54:01 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    AbbVie Inc. Financials

    Live finance-specific insights

    See more
    • AbbVie Reports First-Quarter 2025 Financial Results

      Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis  First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues

      4/25/25 7:43:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host First-Quarter 2025 Earnings Conference Call

      NORTH CHICAGO, Ill., March 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas in

      3/31/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

      Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in needNORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today announced a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity. "At AbbVie, we are focused on trans

      3/3/25 1:11:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Declares Quarterly Dividend

      NORTH CHICAGO, Ill., Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.64 per share.  The cash dividend is payable May 15, 2025, to stockholders of record at the close of business on April 15, 2025. Since the company's inception in 2013, AbbVie has increased its dividend by 310 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorr

      2/13/25 11:57:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

      Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

      2/12/25 7:33:00 AM ET
      $ABBV
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

      Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p

      2/12/25 7:30:00 AM ET
      $ABBV
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results

      Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $56.334 Billion, an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 Billion, an Increase of 2.1 Percent on a Reported Basis, or 2.9 Percent on an Operational Basis; Global Humira Net Revenues Were $8.993 Billion; Global Skyrizi Net Revenues Were $11.718 Billion; Global Rinvoq Net Revenues Were

      1/31/25 7:36:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call

      NORTH CHICAGO, Ill., Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key thera

      1/3/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Reports Third-Quarter 2024 Financial Results

      Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $14.460 Billion, an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.046 Billion, an Increase of 3.9 Percent on a Reported Basis, or 4.8 Percent on an Operational Basis; Global Humira Net Revenues Were $2.227 Billion; Global Skyrizi Net Revenues Were $3.205 Billion; Global Rinvoq Net Revenues W

      10/30/24 7:38:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline

      Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's diseaseAcquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscienceNORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada's lead investigational asse

      10/28/24 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care